What is the clinical evidence from this study?

Study design: Other. Population: Acute myocardial infarction and arterial thrombosis. Intervention: Panax notoginseng saponins (PNS) vs. Saline (AMI control) or Aspirin. Primary outcome: Left ventricular ejection fraction (LVEF) (p=<0.01).

What does this research mean for the field?

Panax notoginseng saponins (PNS) exert anti-platelet and anti-thrombotic effects while preserving basal hemostasis by reprogramming platelet oxylipin metabolism. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

May 23, 2026BMC Complementary Medicine and TherapiesOpen Access

Panax notoginseng saponins inhibit platelet activation and thrombosis while preserving hemostasis: involvement of platelet oxylipin metabolic reprogramming

Q: What are the key findings of this study?

Panax notoginseng saponins significantly improved left ventricular ejection fraction to 57.25% compared to 29.58% in the AMI control group, while inhibiting platelet activation and thrombosis.

Q: What does this research mean for the field?

Panax notoginseng saponins (PNS) exert anti-platelet and anti-thrombotic effects while preserving basal hemostasis by reprogramming platelet oxylipin metabolism. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

Q: What question did this study set out to answer?

This study investigates the effects of Panax notoginseng saponins on platelet function, thrombosis, and hemostasis, particularly focusing on oxylipin metabolism regulation.

View Full Paper

Ask AI

Bookmark

Key result

Panax notoginseng saponins improve LVEF by ~28 points in AMI models while inhibiting platelet activation.

P<0.01

Why the study?

This study aimed to investigate the impact of Panax notoginseng saponins on platelet function, thrombosis, and hemostasis, and to explore mechanisms regarding platelet oxylipin metabolism regulation.

Does Panax notoginseng saponins inhibit platelet activation and thrombosis in animal models of myocardial ischemia and arterial thrombosis?

Population

Rat acute myocardial infarction model and mouse thrombosis and bleeding models

Comparison

Panax notoginseng saponins vs comparator conditions or aspirin

Design

Preclinical animal study and in vitro assays

Authors

WWWenting Wang CLChangkun Li MWMingming Wang

Discussion

Member takes

Overview

May support further rat AMI studies; leaves open translation to human antiplatelet or cardioprotective use.

Key Points

This study investigates the effects of Panax notoginseng saponins on platelet function, thrombosis, and hemostasis, particularly focusing on oxylipin metabolism regulation.
Evaluated effects of PNS in a rat model of acute myocardial infarction (N=...);
Assessed platelet function through flow cytometry and light transmission aggregometry;
Conducted thrombus formation analysis using FeCl3-injured mesenteric arterioles.
PNS significantly inhibited platelet aggregation in a dose-dependent manner, outperforming aspirin (specific metrics not provided);
PNS reduced myocardial injury and infarct expansion post-MI;
PNS preserved hemostasis while favoring anti-thrombotic lipid generation and mitigating pro-inflammatory responses.

Structured PICO

Does Panax notoginseng saponins inhibit platelet activation and thrombosis in animal models of myocardial ischemia and arterial thrombosis?

Population

Male SD rats (weighed 180-220 g) subjected to acute myocardial infarction (AMI) model and male C57BL/6 mice (aged 6-8 weeks) subjected to FeCl3-injured mesenteric arteriole thrombosis model.

Intervention

Panax notoginseng saponins (PNS) administered orally for 7 days at low (10.8 mg/kg/d), intermediate (21.6 mg/kg/d), or high (43.2 mg/kg/d) doses.

Comparator

Saline (sham and model groups) or Aspirin (ASA) administered orally (loading dose 27 mg/kg/d for one day, maintenance dose 9 mg/kg/d for days 2-7).

Outcome

Platelet aggregation (ex vivo), thrombus formation time, and infarct size (in vivo).surrogate

Main Result

Absolute Event Rate: 57.25% vs 29.58%

p-value: p=<0.01

Panax notoginseng saponins demonstrate dose-dependent antiplatelet and antithrombotic effects in preclinical models of myocardial infarction and arterial thrombosis while preserving basal hemostasis.

Cite This Study

Wang et al. (2026) studied Acute myocardial infarction and arterial thrombosis. Panax notoginseng saponins (PNS) vs. Saline (AMI control) or Aspirin was evaluated on Left ventricular ejection fraction (LVEF) (p=<0.01). Panax notoginseng saponins significantly improved left ventricular ejection fraction to 57.25% compared to 29.58% in the AMI control group, while inhibiting platelet activation and thrombosis.

synapsesocial.com/papers/6a1145b048a409a3a49df4ea https://doi.org/10.1186/s12906-026-05401-7

View Full Paper

Ask AI

Bookmark

May 23, 2026BMC Complementary Medicine and TherapiesOpen Access

Panax notoginseng saponins inhibit platelet activation and thrombosis while preserving hemostasis: involvement of platelet oxylipin metabolic reprogramming

View Full Paper

Ask AI

Bookmark

Key result

Panax notoginseng saponins improve LVEF by ~28 points in AMI models while inhibiting platelet activation.

P<0.01

Why the study?

This study aimed to investigate the impact of Panax notoginseng saponins on platelet function, thrombosis, and hemostasis, and to explore mechanisms regarding platelet oxylipin metabolism regulation.

Does Panax notoginseng saponins inhibit platelet activation and thrombosis in animal models of myocardial ischemia and arterial thrombosis?

Population

Rat acute myocardial infarction model and mouse thrombosis and bleeding models

Comparison

Panax notoginseng saponins vs comparator conditions or aspirin

Design

Preclinical animal study and in vitro assays

Authors

WWWenting Wang CLChangkun Li MWMingming Wang

Discussion

Member takes

Overview

May support further rat AMI studies; leaves open translation to human antiplatelet or cardioprotective use.

Key Points

This study investigates the effects of Panax notoginseng saponins on platelet function, thrombosis, and hemostasis, particularly focusing on oxylipin metabolism regulation.
Evaluated effects of PNS in a rat model of acute myocardial infarction (N=...);
Assessed platelet function through flow cytometry and light transmission aggregometry;
Conducted thrombus formation analysis using FeCl3-injured mesenteric arterioles.
PNS significantly inhibited platelet aggregation in a dose-dependent manner, outperforming aspirin (specific metrics not provided);
PNS reduced myocardial injury and infarct expansion post-MI;
PNS preserved hemostasis while favoring anti-thrombotic lipid generation and mitigating pro-inflammatory responses.

Structured PICO

Does Panax notoginseng saponins inhibit platelet activation and thrombosis in animal models of myocardial ischemia and arterial thrombosis?

Population

Male SD rats (weighed 180-220 g) subjected to acute myocardial infarction (AMI) model and male C57BL/6 mice (aged 6-8 weeks) subjected to FeCl3-injured mesenteric arteriole thrombosis model.

Intervention

Panax notoginseng saponins (PNS) administered orally for 7 days at low (10.8 mg/kg/d), intermediate (21.6 mg/kg/d), or high (43.2 mg/kg/d) doses.

Comparator

Saline (sham and model groups) or Aspirin (ASA) administered orally (loading dose 27 mg/kg/d for one day, maintenance dose 9 mg/kg/d for days 2-7).

Outcome

Platelet aggregation (ex vivo), thrombus formation time, and infarct size (in vivo).surrogate

Main Result

Absolute Event Rate: 57.25% vs 29.58%

p-value: p=<0.01

Panax notoginseng saponins demonstrate dose-dependent antiplatelet and antithrombotic effects in preclinical models of myocardial infarction and arterial thrombosis while preserving basal hemostasis.

Cite This Study

synapsesocial.com/papers/6a1145b048a409a3a49df4ea https://doi.org/10.1186/s12906-026-05401-7

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark